Evidence-informed educational review. Updated 10 November 2026. Follow current local product labeling and individualized clinical guidance.
Feeling full after a few bites, nausea and vomiting can occur in gastroparesis. Before choosing a prokinetic, establish that solid food empties slowly and exclude a mechanical obstruction. The 2025 American Gastroenterological Association (AGA) guideline favours a four-hour gastric emptying study. A shorter study can miss delayed emptying. [1, 2]
Classification and mechanisms
- Metoclopramide: antagonizes dopamine D2 receptors and stimulates 5-HT4-mediated enteric acetylcholine activity, improving upper-gastrointestinal motility; also acts centrally as an antiemetic.
- Domperidone: peripheral D2-receptor antagonist with less CNS penetration than metoclopramide but important cardiac/QT risks; access and regulatory status vary by country.
- Erythromycin: macrolide antibiotic that stimulates motilin receptors, promoting gastric antral contractions; tachyphylaxis limits sustained benefit.
- Prucalopride: selective 5-HT4 agonist approved in many settings for chronic idiopathic constipation; not an established first-line gastroparesis drug.
- Other 5-HT4 agonists: regional availability and cardiovascular safety differ. Hyoscine butylbromide has anticholinergic effects and can slow gastrointestinal motility [3, 1, 4].
What treatment should achieve
Ask which problem most affects the patient: completing meals, retaining fluids or controlling vomiting. Review drugs that slow gastric emptying, particularly opioids, and address hyperglycemia in people with diabetes. A diet built around small-particle foods can make meals easier to tolerate. Follow oral intake, weight and symptoms when judging whether a drug is helping. Antiemetics can relieve nausea without accelerating gastric emptying. [2]
Metoclopramide
Metoclopramide blocks dopamine D2 receptors and promotes coordinated upper gastrointestinal motility. Its central action also helps control nausea. The AGA conditionally suggests it for gastroparesis. The US oral Reglan label specifically covers symptomatic acute and recurrent diabetic gastroparesis in adults. Consider renal function, other dopamine-blocking medicines and the patient’s history of movement disorders before prescribing. [1, 4]
The boxed warning concerns tardive dyskinesia, which may persist after withdrawal. Risk increases with cumulative exposure. Use the shortest effective course, review benefit early and generally avoid treatment beyond 12 weeks. New involuntary movements of the face, tongue or limbs warrant stopping metoclopramide and prompt evaluation. Acute dystonia can develop much earlier. Gastrointestinal obstruction, bleeding or perforation are contraindications when stimulating motility could cause harm. [4]
Erythromycin and other options
At prokinetic doses, erythromycin stimulates motilin receptors and can accelerate gastric emptying. Its benefit often wanes with continued exposure, limiting its role in sustained treatment. Review QT-prolonging drugs and interactions before use. The AGA recommendation is conditional, so symptom burden and treatment risks should guide the decision. [1, 2]
Domperidone is a predominantly peripheral dopamine antagonist. Ventricular arrhythmia and sudden cardiac death are important concerns. It lacks US marketing approval, and access through an investigational pathway depends on regulatory and supply arrangements. The AGA advises against starting routinely with either domperidone or prucalopride. Persistent symptoms should prompt review of the diagnosis, nutrition and previous treatment response before moving to these options. [1, 5]
References
- American Gastroenterological Association. Clinical guidance on the management of gastroparesis. 2025. [cited 2026 Nov 10]. View source.
- Camilleri M, Kuo B, Nguyen L, Vaughn VM, Petrey J, Greer K, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol. 2022;117:1197–1220. [cited 2026 Nov 10]. View source.
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- US Food and Drug Administration. Reglan (metoclopramide) prescribing information. Updated February 2026. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/017854s071lbl.pdf
- US Food and Drug Administration. How to request domperidone for expanded access use. 2025. [cited 2026 Nov 10]. View source.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.